TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced that results of the PREVENT-SCD trial, published in the journal Clinical Research in Cardiology, reinforce the value of the Microvolt T-Wave Alternans™ (MTWA) test in identifying patients at risk of Sudden Cardiac Death (SCD). Preliminary results of the study were originally presented at the American Heart Association Scientific Sessions in 2009.